Intervention

Firmonertinib

ClinicalTrials.gov intervention label

Clinical trials4

Recruiting2

Common conditions12

Lead sponsors shown4

Clinical trials

4 shown

Firmonertinib Combined With Definitive Radiotherapy in Stage III Unresectable EGFR Uncommon Mutant Pulmonary AdenocarcinomaNCT07314216 · 2026-06-22

Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon MutationsNCT07185997 · 2025-12-17

A Prospective Study of Firmonertinib as First-line Adaptive Therapy Guided by Dynamic ctDNA (MRD) Changes in Locally Advanced or Metastatic EGFR-mutated Non-small Cell Lung CancerNCT07661173 · 2026-06-06

NOT_YET_RECRUITING

Firmonertinib in the Treatment of EGFR(+) NSCLC Patients With Central Nervous System MetastasisNCT07239102 · 2020-01-01

Common conditions

EGFR Uncommon Mutations2 Advanced Non-Small-Cell Lung Cancer1 Central Nervous System Metastasis1 EGFR P-Loop and Alpha C-Helix Compressing1 EGFR PACC1 EGFR Positive Non-small Cell Lung Cancer1 Leptomeningeal Metastasis1 Metastatic Non-Small-Cell Lung Cancer1 Non Small Cell Lung Cancer1 Non-Small-Cell Lung Cancer1 NSCLC (Non-small Cell Lung Carcinoma)1 Stage III1

Leading sponsors

Anhui Provincial Cancer Hospital1 ArriVent BioPharma, Inc.1 Beijing Tiantan Hospital1 Hunan Cancer Hospital1

Trial status mix

RECRUITING2

COMPLETED1

NOT_YET_RECRUITING1

Phase mix

PHASE22

PHASE31

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.